Nisa Investment Advisors
CADL icon

Nisa Investment Advisors’s Candel Therapeutics CADL Stock Holding History

Nisa Investment Advisors’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$494 Hold
48
– – ﹤0.01% 2948
2026
Q1 		$235 Hold
48
– – ﹤0.01% 2976
2025
Q4 		$271 Hold
48
– – ﹤0.01% 2894
2025
Q3 		$245 Hold
48
– – ﹤0.01% 2942
2025
Q2 		$243 Buy
48
+4
+9% +$21 ﹤0.01% 2974
2025
Q1 		$249 Buy
44
+21
+91% +$172 ﹤0.01% 2896
2024
Q4 		$200 Sell
23
-55
-71% -$325 ﹤0.01% 2932
2024
Q3 		$541 Buy
+78
New +$485 ﹤0.01% 2711

Other funds holding CADL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $617M AUM 69.99% 1-Year Est. Return
TWM
Tanager Wealth Management Goring On Thames, United Kingdom $1.15B AUM 19.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
TGIA
Torrey Growth & Income Advisors Del Mar, California $294M AUM 37.95% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Nisa Investment Advisors's CADL Position: Q2 2026 in Review

Nisa Investment Advisors held its Candel Therapeutics (CADL) position steady in Q2 2026 at 48 shares worth $494. The position accounts for ﹤0.01% of the portfolio, ranked #2948.

Nisa Investment Advisors first reported a position in CADL in Q3 2024 and has held it in 8 quarters since. The position peaked at $541 in Q3 2024. 51 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Nisa Investment Advisors held 48 shares of Candel Therapeutics worth $494 as of Q2 2026.
  • Nisa Investment Advisors left its Candel Therapeutics share count unchanged in Q2 2026.
  • Candel Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2948 holding.
  • Nisa Investment Advisors first reported a position in Candel Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Nisa Investment Advisors's Candel Therapeutics position peaked at $541 in Q3 2024.
  • 51 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.